Login
Related Links
New and Updated Clinical Gene Therapy Trials
Gene therapy studies updated or received in the last 30 days at ClinicalTrials.gov. Only open studies, recruiting or not yet recruiting, are shown found by a search using the keyword: "gene therapy OR gene transfer OR virus delivery"
-
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
24 April 2025Conditions: Diabetic Macular Edema Interventions: Genetic: RGX-314 Dose 1; Genetic: RGX-314 Dose 2; Biological: Aflibercept (2.0 mg) Sponsors: Sierra Eye Associates; REGENXBIO Inc. Recruiting
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
24 April 2025Conditions: Stargardt Disease; Stargardt Macular Degeneration; Stargardt Macular Dystrophy Interventions: Genetic: SB-007 Sponsors: Splice Bio Recruiting
-
A First-in-human Clinical Trial Using a Gene Therapy With Patient's Own Stem Cells to Treat Early Type 1 Diabetes
22 April 2025Conditions: Diabetes, Type I Interventions: Genetic: Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNA Sponsors: Altheia Science; Evidenze Health S.r.l. Not yet recruiting
-
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
18 April 2025Conditions: T-Cell Acute Lymphoblastic Leukemia/Lymphoma Interventions: Biological: Allogeneic anti-CD7 CAR-T cells (BEAM-201) Sponsors: Stephan Grupp MD PhD; Beam Therapeutics Inc. Not yet recruiting
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
13 April 2025Conditions: SLE (Systemic Lupus); Lupus Erythematosus, Systemic; Lupus Nephritis; Systemic Sclerosis; Inflammatory Myopathy, Idiopathic; Myositis; Diffuse Cutaneous Systemic Sclerosis Interventions: Biological: CTX112 Sponsors: CRISPR Therapeutics Recruiting
-
First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury
13 April 2025Conditions: Spinal Cord Injury; Chronic Spinal Cord Injury Interventions: Drug: STUP-001 Sponsors: Yonsei University; Stand Up Therapeutics INC. Not yet recruiting
-
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
10 April 2025Conditions: Primary Open-Angle Glaucoma (POAG) Interventions: Drug: GVB-2001-high dose; Drug: GVB-2001-low dose Sponsors: IVIEW Therapeutics Inc.; The First Affiliated Hospital of Soochow University Not yet recruiting
-
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
06 April 2025Conditions: Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant; Recurrent Malignant Brain Neoplasm; Resectable Brain Neoplasm Interventions: Genetic: Ad-hCMV-Flt3L; Genetic: Ad-hCMV-TK; Procedure: Biospecimen Collection; Procedure: Magnetic Resonance Imaging; Other: Survey Administration; Procedure: Tumor Resection; Drug: Valacyclovir Sponsors: University of Michigan Rogel Cancer Center Not yet recruiting
-
DFT383 in Pediatric Participants With Nephropathic Cystinosis
04 April 2025Conditions: Nephropathic Cystinosis Interventions: Genetic: DFT383 Sponsors: Novartis Pharmaceuticals Not yet recruiting
-
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
25 April 2025Conditions: Malignancy, Hematologic; Neoplasms, Hematologic; Neoplasms, Hematopoietic; Blood Cancer; Hematological Neoplasms; Hematopoietic Malignancies; Dysmyelopoietic Syndromes; Hematopoetic Myelodysplasia; Myeloid Leukemia, Acute; Nonlymphoblastic Leukemia, Acute; Leukemia, Lymphocytic, Acute Interventions: Drug: aldesleukin; Drug: cyclophosphamide; Drug: fludarabine phosphate; Biological: Individual Patient TCR-Transduced PBL; Device: TruSight Oncology (TSO) 500 Sponsors: National Cancer Institute (NCI) Not yet recruiting
-
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
06 April 2025Conditions: B-Cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia Interventions: Drug: DuoCAR20.19.22-D95; Drug: Fludarabine (Conditional therapy); Drug: Cyclophosphamide (Conditional therapy) Sponsors: University of Kansas Medical Center Recruiting
-
Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy
25 April 2025Conditions: X-linked Severe Combined Immunodeficiency; X-SCID; XSCID Interventions: Genetic: Plerixafor; Drug: Filgrastim; Drug: Palifermin; Drug: Busulfan; Biological: Base-edited hematopoietic stem and progenitor cells Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
-
To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
24 April 2025Conditions: Hemophilia A Interventions: Drug: GS1191-0445 injection Sponsors: Gritgen Therapeutics Co., Ltd. Recruiting
-
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
24 April 2025Conditions: Duchenne Muscular Dystrophy Interventions: Genetic: INS1201 Sponsors: Insmed Gene Therapy LLC Recruiting
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
16 April 2025Conditions: Squamous Cell Carcinoma Interventions: Drug: BVEC Sponsors: Stanford University; Epidermolysis Bullosa Research Partnership Recruiting
-
A Study of EH002 Gene Therapy for Otoferlin Gene Mutation-mediated Hearing Loss
30 March 2025Conditions: DFNB9; Congenital Hearing Loss; Hearing Loss, Sensorineural Interventions: Genetic: EH002 administration Sponsors: Yilai Shu Recruiting
-
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
25 April 2025Conditions: Gastrointestinal Carcinoma; Pancreatic Cancer; Hepatocellular Cancer; Cholangiocarcinoma; Duodenal Cancer; Colorectal Cancer; Small Bowel Cancer; Metastatic Cancers Interventions: Biological: KRAS TCR-Transduced PBL; Drug: Aldesleukin; Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: National Cancer Institute (NCI) Recruiting
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
02 April 2025Conditions: Solid Tumor, Adult; Colorectal Cancer; Non-Small Cell Lung; NSCLC (Non-small Cell Lung Cancer); Cancer; Colon Cancer; Rectal Cancer; Lung Cancer; CRC; Head and Neck Squamous Cell Cancer; HNSCC; Renal Cell Carcinoma; RCC; Kidney Cancer; Triple Negative Breast Cancer; TNBC; Colorectal Adenocarcinoma Interventions: Biological: A2B395; Diagnostic Test: xT CDx with HLA-LOH assay Sponsors: A2 Biotherapeutics Inc. Recruiting
-
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
02 April 2025Conditions: X-Linked Retinitis Pigmentosa Interventions: Biological: AAV5-hRKp.RPGR; Other: No intervention (Follow-Up assessment) Sponsors: Janssen Research & Development, LLC Recruiting
-
Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy
23 April 2025Conditions: Hemoglobin Disorder Sponsors: St. Jude Children's Research Hospital Recruiting
-
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
04 April 2025Conditions: Chronic Granulomatous Disease; Granulomatous Disease, Chronic Interventions: Biological: PM359 Sponsors: Prime Medicine, Inc. Recruiting
-
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
23 April 2025Conditions: Non-muscle Invasive Bladder Cancer With Carcinoma in Situ Interventions: Drug: Nadofaragene Firadenovec; Drug: Gemcitabine; Drug: Docetaxel; Drug: Pembrolizumab Sponsors: Ferring Pharmaceuticals Recruiting
-
A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)
16 April 2025Conditions: Cystic Fibrosis Interventions: Genetic: BI 3720931; Drug: Placebo; Device: Inhaler Sponsors: Boehringer Ingelheim Recruiting
-
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
08 April 2025Conditions: Intermediate Risk Non-Muscle Invasive Bladder Cancer Interventions: Drug: Nadofaragene Firadenovec Sponsors: Ferring Pharmaceuticals Recruiting
-
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
17 April 2025Conditions: Age Related Macular Degeneration (ARMD) Interventions: Drug: Elamipretide; Drug: Placebo Sponsors: Stealth BioTherapeutics Inc. Recruiting
-
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
23 April 2025Conditions: Beta-Thalassemia Interventions: Biological: ALS20 Sponsors: Children's Hospital of Philadelphia Recruiting
-
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
24 April 2025Conditions: Chronic Granulomatous Disease (CGD); X-Linked Chronic Granulomatous Disease Interventions: Biological: Base-edited hematopoietic stem and progenitor cells; Drug: Busulfan; Drug: Palifermin; Drug: Filgrastim; Drug: Plerixafor Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) Suspended
-
Natural History Study in Patients with PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa
30 March 2025Conditions: Retinitis Pigmentosa Sponsors: University Hospital Tuebingen Recruiting
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
24 April 2025Conditions: Parkinson Disease Interventions: Drug: AAV2-GDNF Gene therapy; Procedure: Control Surgery Sponsors: AskBio Inc; Bayer Recruiting
-
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
11 April 2025Conditions: Fabry Disease Interventions: Drug: AMT-191 Sponsors: UniQure Biopharma B.V. Recruiting
Info ClinicalTrials.gov
Clinical gene therapy trials recently received at ClinicalTrials.gov database.
The U.S. National Institutes of Health, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members and members of the public current information about clinical research studies. The database is a registry of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details.
 |
Latest clinical trials |
|
Search clinical trials |
The U.S. National Institutes of Health, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members and members of the public current information about clinical research studies. The database is a registry of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details.
Participate in Trial
Are you a patient and considering to participate in a clinical gene therapy trial? Your doctor may be an excellent resource to help identify clinical trials for a particular disease. There are a number of online resources that can also assist in locating clinical trials that are accepting patients:
|
ClinicalTrials.gov |
|
Cancer.gov |
|
CenterWatch |
When looking for a clinical trial, remember to make sure the trial is appropriate for the disease. Most trials also specify an age range for the participants. Additional eligibility requirements must also be met, but these will vary depending on the individual study. Contact the health professionals if they are not listed. It is always best to discuss these issues before you travel to gene therapy center. More clinical trial information.
Be aware that Gene Therapy Net is not intended to replace or constitute the giving of medical treatments or advice.